Password reminder
No account yet? Register Free
About Us Advertising Info Contact Us Client Login
biotechdaily.com
Biochemistry
Features Subscription Partner Sites Journal Info
ROCHE APPLIED SCIENCEHTL Lab SolutionsSANYO EUROPE LTD

Study Provides Insights into How Absent Reoviruses Kill Cancer

By BiotechDaily International staff writers
Posted on 02 Mar 2011


Reoviruses are effectively being used in clinical trials to treat patients with cancer.

Not only does the virus cause cancer cells to die, it also forces them to release proinflammatory chemokines and cytokines, which then causes the patient's immune system to fight the disease. New research has also revealed that reovirus infected cancer cells secrete proteins that, even when isolated, result in the death of cancer cells.

Normal human cells are protected from reovirus infection by a protein called PKR. However, a cellular signaling protein (Ras), which can block PKR activity, is abnormally triggered in many types of cancer, and it provides a window of opportunity for reovirus infection. A multicenter study, involving laboratories in the United Kingdom and the United States, gathered growth media from reovirus infected melanoma cells. The researchers showed that this media contained a range of small proinflammatory proteins, including an interleukin (IL-8) and type 1 interferon (INF-β), which recruited and activated white blood cells, specifically natural killer (NK) cells, dendritic cells (DCs), and antimelanoma cytotoxic T cells (CTLs).

While the precise details behind this mode of action of cell signaling in response to viral infection are unclear, the release of cytokines was dependent on both "inactive" PKR and a specific nuclear factor (NF-κβ). According to Prof. Alan Melcher, from the Leeds Institute of Molecular Medicine (UK), and one of the investigators of the study, "bystander immune-mediated therapy may well be an important component in the treatment of cancer by reoviruses, and may have potential in treating cancer even in the absence of live virus."

The study's findings were published February 20, 2011, by BioMed Central's open access journal Molecular Cancer.

Related Links:
Leeds Institute of Molecular Medicine






Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to BiotechDaily.com and get complete access to news and events that shape the world of biotechnology.
Free digital version edition of Bio Research International sent by email on regular basis
Free print version of Bio Research International magazine
(available only outside USA and Canada).
Free and unlimited access to back issues of Bio Research International in digital format
Free Bio Research International Newsletter sent every 2 weeks containing the latest news
Free breaking news sent via email
Free access to Events Calendar
Free access to LinkXpress new product services
REGISTRATION IS FREE AND EASY!


Click here to Register

Sign in: Registered website members
Username: Password:
Forgot username/password? Click here!
Sign in: Registered magazine subscribers
Subcode: Last Name:
What is SUBCODE?

ADVERTISEMENT
GLOBETECH PUBLISHING



PCR Workstation
PCR Workstation
Data Storage / Analysis System
Data Storage / Analysis System
Electronic Pipettes
Electronic Pipettes

More Products

Latest Biochemistry News

LinkXpress
Click for LinkXpress
Reader Inquiry Service
Enter code to receive information:
Where I can find code?
Featured Video
BioTek:
The Race

View Video
Featured Whitepaper
ELGA LABWATER:
Why pure water is important in modern chromatography

Download Whitepaper
Events
ELA 2012 - European Lab Automation.
30 May 2012 - 31 May 2012


Bio International 2012.
18 Jun 2012 - 21 Jun 2012


ACHEMA 2012.
18 Jun 2012 - 22 Jun 2012


More events
Latest Issue

View Digital Edition
Subscribe / Renew
BRAND GMBH + CO
HTL Lab Solutions
VISION-SCIENCES, INC.
WEALTEC BIOSCIENCE CO. LTD
  biotechdaily.com Copyright © 2000-2012 Globetech Media. All rights reserved.
Privacy Policy